The Week In... Pharma (27-31/05)
  • Posted on: 31/05/2019
  • Category: Industry

The Week In... Pharma (27-31/05)

England is seeing the highest ever clinical trial participation rate, a new molecular diagnostics business is launched in Manchester, and the NHS accuses Theresa May of not tackling the “country’s biggest injustices”.

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at ryan.wooller@starmedical.co.uk, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring!

Theresa May failed to tackle “country’s biggest injustices”, says NHS

Current prime minister Theresa May is set to step down on 7 June, after a teary speech in which she said she had helped give “voice to the voiceless” with her contributions to the NHS during her time in the position.

Novartis scores first approval for PIK3CA breast cancer drug

The FDA has approved Novartis’ breast cancer drug Piqray (alpelisib), making it the first marketed treatment targeting the PIK3CA mutation in this disease.

New molecular diagnostics business launched in Manchester

Health Innovation Manchester and global partner QIAGEN has announced the creation of a new company to develop new tests for the prediction, prevention, and diagnosis of disease.

European elections: Eurosceptics and Greens rise, but big parties hold on

After predictions that the EU’s political map could be hit by an earthquake, results from the European Parliamentary elections show the centre-ground parties have survived with a medium-sized tremor.

England sees highest ever clinical trial participation rates: NIHR

Clinical research in England is growing at a record-setting pace with support from a recent £20.5bn investment to transform service delivery – as the NHS looks to conduct more studies in primary care settings.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.